Infectious Disease Research Institute

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »

First vaccine for fatal visceral leishmaniasis enters clinical trial

Monday, February 27, 2012 10:08 AM

Seattle-based nonprofit Infectious Disease Research Institute (IDRI) has teamed up with India-based Gennova Biopharmaceuticals to target visceral leishmaniasis (VL), launching a phase I trial of vaccine for the infection disease.

More... »

IDRI supports first phase I human hookworm vaccine trial

Wednesday, February 1, 2012 04:01 PM

The Infectious Disease Research Institute (IDRI) has joined Sabin Vaccine Institute's venture to develop a human hookworm vaccine—which affects 600 million people worldwide—by contributing a proprietary adjuvant as a component. The phase I trial, which began last week in Brazil, aims to reduce the global burden of human hookworm by providing effective long-term protection for those who are most at risk.

More... »

Lilly awards IDRI $4 million in tuberculosis research funding

Tuesday, November 22, 2011 10:55 AM

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly. The funding will support IDRI’s continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB).

More... »

IDRI joins ADITEC to accelerate human vaccine development

Tuesday, October 18, 2011 02:19 PM

The Infectious Disease Research Institute (IDRI) has joined the Advanced Immunization Technologies (ADITEC) program, a collaborative initiative dedicated to accelerating the development of the next generation of human vaccines. Launched on October 1st, ADITEC will operate with 30 million euros in funding over the course of 5 years contributed by the European Union, with an additional 11 million euros in funding from collaborating organizations.

More... »

IDRI awarded $300k grant for TB vaccine clinical program

Thursday, October 13, 2011 10:25 AM

The Infectious Disease Research Institute (IDRI) has been awarded a two-year $300,000 grant from The Paul G. Allen Family Foundation to support IDRI's launch of a phase I clinical trial of its new tuberculosis vaccine known as ID93/GLA-SE.  The phase I trial will evaluate the safety and immunogenicity of ID93/GLA-SE in a group of healthy volunteers, and is expected to begin in early 2012.

More... »